In addition to predicting the response to EGFR-targeted therapy, the KRAS, NRAS, BRAF, and PIK3CA mutations may also act as significant prognostic factors in CRC (Foltran et al. 2015; Vogelaar et al. 2015). The gene discussed is NRAS; the disease is colorectal carcinoma.